Mersana Therapeutics announced positive initial clinical data for its drug Emi-Le (XMT-1660) in a Phase 1 trial, with a confirmed objective response rate of 23% in a specific patient group, and received an additional FDA Fast Track designation for advanced breast cancer treatment.